Moderna (CHIX:0QFD) YoY EPS Growth: 7.42% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:0QFD Moderna Inc CHIX:0QFD
56 GF Score
Price €123.18
GF Value €21.93
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Moderna YoY EPS Growth?

Moderna CHIX:0QFD 56 YoY EPS Growth is 7.42% as of Jun. 2026. GuruFocus rates CHIX:0QFD with a GF Score™ of 56/100 and a GF Value™ of €21.93 (Significantly Overvalued). The stock has 7 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Moderna's YoY EPS Growth for the quarter that ended in Jun. 2026 was 7.42%.

Moderna's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was €-1.71.

Moderna YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Moderna's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moderna YoY EPS Growth Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,654.13 -24.14 -159.53 21.62 30.04

Moderna Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.30 -1,711.11 35.16 -26.17 7.42
CHIX:0QFD
56GF Score
Moderna Inc CHIX:0QFD
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moderna YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Moderna's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-6.2--8.862)/ | -8.862 |
=30.04 %

Moderna's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-1.71--1.847)/ | -1.847 |
=7.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 7.42% mean?
Moderna (CHIX:0QFD) has a YoY EPS Growth of 7.42% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Moderna and its competitors.
Is Moderna's YoY EPS Growth too high?
Moderna's current YoY EPS Growth is 7.42%. Overall, Moderna has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Moderna's YoY EPS Growth compare to RVMD and ONC?
Moderna's YoY EPS Growth of 7.42% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Moderna and its competitors. Moderna's current YoY EPS Growth is 7.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Based on GuruFocus' analysis, Moderna (CHIX:0QFD) is currently considered Significantly Overvalued. The stock's GF Value™ is €21.93, compared to a current price of €123.18 — trading 461.7% above its estimated fair value. The current YoY EPS Growth is 7.42%. Moderna's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Moderna (CHIX:0QFD), the current YoY EPS Growth is 7.42% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moderna (CHIX:0QFD) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of €123.18 is trading 461.7% above its estimated GF Value™ of €21.93. GuruFocus considers Moderna to be Significantly Overvalued.

Key valuation signals for CHIX:0QFD:

  • YoY EPS Growth: 7.42%
  • GF Value™: €21.93 vs. price of €123.18 (461.7% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
56GF Score

Get the complete analysis for CHIX:0QFD

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€123.18
Price
€21.93
GF Value